Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: sun who wrote (1859)	7/10/1999 11:35:00 PM
From: Land Shark	Read Replies (1) \| Respond to of 10293

Oh, where are the clinical trials? Show me the money!

To: sun who wrote (1859)	7/11/1999 12:36:00 AM
From: BDR	Read Replies (1) \| Respond to of 10293

ama-assn.org Abstracts - May 19, 1999 Efficacy of Tremacamra, a Soluble Intercellular Adhesion Molecule 1, for Experimental Rhinovirus Infection Results A total of 88 (92%) of the 96 subjects in the placebo groups and 69 (85%) of the 81 subjects in the active treatment groups were infected (P=.19). For placebo vs tremacamra, respectively, the total symptom score (± 95% confidence interval [CI]) was 17.6 (± 2.7) vs 9.6 (± 2.9), the proportion of clinical colds was 64/96 (67% ± 9%) vs 36/81 (44% ± 11%), and the nasal mucus weight was 32.9 (± 8.8) g vs 14.5 (± 9.4) g (P<.001 for all comparisons). Tremacamra was not associated with adverse effects or evidence of absorption through the nasal mucosa and did not interfere with development of neutralizing antibody. Conclusion Tremacamra reduced the severity of experimental rhinovirus colds. Whether tremacamra will be useful clinically will require further study. Because of the small numbers of subjects the initial difference in rate of infection could have been a random event and not due to the intervention (p=.19) and so I am not sure how significant any of the other differences noted were.